

### Research synthesis: An important element for evidence informed decision making

T Young

Centre for Evidence-based Health Care

www.sun.ac.za/cebhc

Department of Interdisciplinary Health Sciences Faculty of Medicine and Health Sciences Stellenbosch University



### Alarming burden

Chronic disease of lifestyle are the leading cause of death and disability worldwide.

-will cause over 75% of all deaths by 2030
-> 80% of deaths from chronic disease occur in low and middle income countries
- in South Africa, CDL are amongst the top 10 causes of premature mortality

#### South Africans with CDL risk factors: $\geq$ 15 years

Risk factor	Estimated number affected
Smoking tobacco	7.7 million
High BMI	9.1 million
Hypertension	6.3 million
Diabetes II	0.9 million
High blood cholesterol	7.9 million
Low fruit and veg	13.4 million
Physical inactivity	13.6 million

Source: South African Comparative Risk Assessment Norman et al, 2007

## Implementing response: various questions



# Research synthesis is an important approach to find answers

- 'Research synthesis is the process through which two or more research studies are assessed with the objective of summarizing the evidence relating to a particular question.'
- 'The results of a particular research study cannot be interpreted with any confidence unless it has been considered together with the results of other studies addressing the same or similar questions.'

The process of research synthesis is thus the application, in practice, of the principle that science is cumulative.

### It informs...

- New research
- Decision making for action

Research synthesis is research, so - as in all research – scientifically defensible steps must be taken to reduce:

- biases of various kinds
- the effects of the play of chance
- and, thus, the danger of false conclusions

Up to date, relevant and robust systematic reviews

# Systematic reviews have several advantages

- reduce risk of bias in selecting and interpreting the results of studies.
- reduce risk of being misled by play of chance in identifying studies for inclusion or risk of focusing on a limited subset of relevant evidence.
- provide a critical appraisal of available research and place individual studies or subgroups of studies in context of all of relevant evidence.
- allow others to appraise critically judgements made in selecting studies and collection, analysis and interpretation of results.

Lavis JN, Posada FB, Haines A, Osei E: Use of research to inform public policymaking. Lancet 2004; 364:1615-21.

#### Metabolic and Endocrine disorder Group

**Tobacco addiction Group** 

#### Heart Group

Hypertension Group



Public Health Group

Stroke Group

#### http://www.cochrane.org/ http://www.thecochranelibrary.com/

Effective Practice and organisation of care Group

Airways Group

St	atins for the primary prevention of Risk factor	Number of reviews in <i>The</i> <i>Cochrane Library</i> (Cochrane and non-Cochrane) – Issue 5, 2012	
Inte Effective Psycho	Smoking tobacco	92	
	High BMI	323	lren
	Hypertension	520	
	Diabetes II	663	
	High blood cholesterol	220	ase
	Low fruit and veg	25	;e
	Physical inactivity	295	

Does reducing saturated fat intake, by reducing and/or modifying dietary fat, in the longer term (at least 6 months) reduce mortality, cardiovascular mortality or cardiovascular morbidity (or individual health events such as myocardial infarction, stroke, diabetes or cancer)?

 Protective of cardiovascular events overall reduction of 14%
 (RR 0.86, 95% CI 0.77 to 0.96; 24 comparisons; 65,614 participants)
 ⊕⊕⊕⊙ moderate GRADE evidence

Moderate: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Hooper 2012

## Statins for the primary prevention of cardiovascular disease

Review: Statins for the primary prevention of cardiovascular disease

Comparison: 2 Montality and Morbidity

Outcome: I Total Mortality

Study or subgroup	Statin Therapy Group	Usual Care or Placebo	Risk Ratio	Weight	Risk Ratio		
	n/N	n/N	M-H,Fixed,95% CI		M-H,Fored,95% CI		
ACAPS 1994	0/460	4/459	·	1.0 %	0.11 [ 0.01, 2.05 ]		
Adult Japanese MEGA Study	57/3958	81/4051		185 %	0.72 [ 0.51, 1.01 ]		
AFCAPS/TexCAPS 1998	80/3304	77/3301	+	17.8 %	1.04 [ 0.76, 1.41 ]		
ASPEN 2006	44/959	40/946	+	9.3 %	1.09 [ 0.71, 1.65 ]		
CARDS 2004	61/1428	82/1410		19.1 %	0.73 [ 0.53, 1.01 ]		
KAPS 1995	4/214	5/212		1.2 %	0.79 [ 0.22, 2.91 ]		
PREVEND IT 2004	10/433	8/431	<del></del> +	1.9 %	1.24 [ 0.50, 3.12 ]		
WOSCOPS 1997	106/3302	135/3293	-	31.2 %	0.78 [ 0.61, 1.01 ]		
Total (95% CI)	14058	14103	•	100.0 %	0.84 [ 0.73, 0.96 ]		
Total events 362 (Statin Therapy Group), 432 (Usual Care or Placebo)							
Heterogeneity: Chi <sup>2</sup> = 7.57, di = 7 (P = 0.37); I <sup>2</sup> = 8%							
Test for overall effect: Z = 2.53 (P =	= 0.011)						
Test for subgroup differences: Not a	pplicable						
			02 0.5 1 2 5				

Favours treatment

Favours control

 14 RCTs (34,272 participants) - High risk patients (raised lipids, diabetes, hypertension, microalbuminuria)

- All-cause mortality RR 0.84, 95% CI 0.73 to 0.96
- Combined fatal and non-fatal CVD endpoints RR 0.70, 95% CI 0.61 to 0.79
- Total cholesterol and LDL cholesterol were reduced in all trials

Taylor 2007

Research Training Translation

## CEBHC: Conducting and supporting conduct of systematic reviews

- Identifying relevant review topics
- Conducting range of systematic reviews
- Provide methodological support and mentorship

Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders<sup>®</sup> for the treatment of chronic disorders (Review)

Schoonees A, Visser J, Musekiwa A, Volmink J



This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Cochrane Library* 2012, Issue 4

http://www.thecochranelibrary.com



Pycnogenol® (extract of French maritime pine bark) for the treatment of chronic disorders<sup>®</sup> for the treatment of chronic disorders (Review) Copyright 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



#### **PUSH:** Summaries of systematic reviews

- Heart and Stroke Foundation monthly emails
- SUPPORT summaries

#### **DIALOGUE:** Participating in SO4 working group Healthy lifestyle

Actionable messages

**PUSH:** Evidence informed policy brief on Continuity of care for chronic diseases

Systematic reviews of research

ndividual studies, articles, and reports

**PULL:** Responsive input on evidence from systematic reviews

**HSFSA** Resource Manual

 Basic, theoretical and methodological ini update



## **CEBHC: Supporting training in systematic reviews and EBHC**

- Support and mentorship for systematic reviews
- Workshops How to read systematic reviews
- Supporting the MSc Clinical Epidemiology <u>www.sun.ac.za/clinepi</u>
  - Systematic review
  - Clinical guidelines
  - Health Systems and Services Research

### **Collaborative engagement with CDIA**

- Identification of relevant topics for systematic reviews
- Conduct relevant systematic reviews
- Support and mentor review conduct
- Increase the use of evidence from systematic reviews in decision making
  - Reactive to needs
  - Enhancing capacity to read systematic reviews

We will serve the public more responsibly and ethically when research designed to reduce the likelihood that we will be misled by bias and the play of chance has become an expected element of professional and policy making practice, not an optional add-on.

#### **Iain Chalmers**



### Acknowledgements

SURE (<u>http://www.evipnet.org/local/SURE%20Website/hom</u> <u>e%20page.htm</u>) EHCRC (<u>http://www.liv.ac.uk/evidence/index.htm</u>) SUPPORT (<u>www.support-collaboration.org</u>)